Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival


Дәйексөз келтіру

Толық мәтін

Аннотация

Background:Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months.

Case Presentation:Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib.

Result:This resulted in a progression-free survival of over 26 months without significant toxic side effects.

Conclusion:Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.

Авторлар туралы

ShuangYi Lei

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

ShanShan Tian

Pre-Hospital Emergency Department, Chongqing Emergency Medical Center, Chongqing University Central Hospital

Email: info@benthamscience.net

SongMei Lu

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Email: info@benthamscience.net

Zhou Qing

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Email: info@benthamscience.net

JianLin Long

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Email: info@benthamscience.net

LuChun Li

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Email: info@benthamscience.net

Dan Yang

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Bégin, L.R.; Eskandari, J.; Joncas, J.; Panasci, L. Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lung. J. Surg. Oncol., 1987, 36(4), 280-283. doi: 10.1002/jso.2930360413 PMID: 2826922
  2. Han, A.; Xiong, M.; Zong, Y. Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am. J. Clin. Pathol., 2000, 114(2), 220-226. doi: 10.1309/148K-ND54-6NJX-NA61 PMID: 10941337
  3. Chang, Y.L.; Wu, C.T.; Shih, J.Y.; Lee, Y.C. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am. J. Surg. Pathol., 2002, 26(6), 715-723. doi: 10.1097/00000478-200206000-00004 PMID: 12023575
  4. Castro, C.Y.; Ostrowski, M.L.; Barrios, R.; Green, L.K.; Popper, H.H.; Powell, S.; Cagle, P.T.; Ro, J.Y. Relationship between epstein-barr virus and lymphoepithelioma-like carcinoma of the lung: A clinicopathologic study of 6 cases and review of the literature. Hum. Pathol., 2001, 32(8), 863-872. doi: 10.1053/hupa.2001.26457 PMID: 11521232
  5. Zhou, Y. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease. Lung Cancer, 2019, 138, 116-123.
  6. Archwamety, A.; Ruangchira-urai, R.; Akewanlop, C.; Korphaisarn, K. Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review. Thorac. Cancer, 2022, 13(17), 2539-2541. doi: 10.1111/1759-7714.14580 PMID: 35830974
  7. Fang, W.; Hong, S.; Chen, N.; He, X.; Zhan, J.; Qin, T.; Zhou, T.; Hu, Z.; Ma, Y.; Zhao, Y.; Tian, Y.; Yang, Y.; Xue, C.; Tang, Y.; Huang, Y.; Zhao, H.; Zhang, L. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget, 2015, 6(32), 33019-33032. doi: 10.18632/oncotarget.5028 PMID: 26361045
  8. Yi, M.; Jiao, D.; Qin, S. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer, 2019, 18(1), 60. doi: 10.1186/s12943-019-0974-6
  9. Chang, Y.L.; Wu, C.T.; Shih, J.Y.; Lee, Y.C. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma‐like carcinomas. Cancer Sci., 2011, 102(1), 282-287. doi: 10.1111/j.1349-7006.2010.01768.x PMID: 21070477
  10. Curcio, L.D.; Cohen, J.S.; Paz, I.B.; Grannis, F.W., Jr; Chilcote, R.; Weiss, L.M. Primary lymphoepithelioma-like carcinoma of the lung in a child. Report of an Epstein-Barr virus-related neoplasm. Chest, 1997, 111(1), 250-251. doi: 10.1378/chest.111.1.250 PMID: 8996028
  11. Hoxworth, J.M.; Hanks, D.K.; Araoz, P.A.; Elicker, B.M.; Reddy, G.P.; Webb, W.R.; Leung, J.W.T.; Gotway, M.B. Lymphoepithelioma-like carcinoma of the lung: Radiologic features of an uncommon primary pulmonary neoplasm. AJR Am. J. Roentgenol., 2006, 186(5), 1294-1299. doi: 10.2214/AJR.05.0244 PMID: 16632721
  12. Chan, J.K.C.; Hui, P.K.; Tsang, W.Y.W.; Law, C.K.; Ma, C.C.; Yip, T.T.C.; Poon, Y.F. Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer, 1995, 76(3), 413-422. doi: 10.1002/1097-0142(19950801)76:33.0.CO;2-X PMID: 8625122
  13. Yoshino, N.; Kubokura, H.; Yamauchi, S.; Ohaki, Y.; Koizumi, K.; Shimizu, K. Lymphoepithelioma-like carcinoma of the lung. Jpn. J. Thorac. Cardiovasc. Surg., 2005, 53(12), 653-656. doi: 10.1007/BF02665079 PMID: 16408473
  14. Xie, M.; Wu, X.; Wang, F. Clinical significance of plasma epstein-barr virus DNA in pulmonary Lymphoepithelioma-like Carcinoma (LELC). Patients. J. Thorac. Oncol., 2018, 13(2), 218-227. doi: 10.1016/j.jtho.2017.10.031
  15. Han, A.; Xiong, M.; Gu, Y.; Lin, S.; Xiong, M. Lymphoepithelioma-like carcinoma of the lung with a better prognosis. A clinicopathologic study of 32 cases. Am. J. Clin. Pathol., 2001, 115(6), 841-850. doi: 10.1309/BUAN-BGFW-69U9-C3H8 PMID: 11392880
  16. Xie, Z.; Liu, L.; Lin, X. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Modern Pathol., 2020, 33, 626-638. doi: 10.1038/s41379-019-0391-9
  17. Kim, C.; Rajan, A.; Debrito, P.A.; Giaccone, G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: A case report and focused review of literature. Transl. Lung Cancer Res., 2016, 5(6), 720-726. doi: 10.21037/tlcr.2016.11.06 PMID: 28149767
  18. Narayanan, A.; Knollmann, F.D.; Walby, J. EBV positive primary pulmonary Lymphoepithelioma-Like Carcinoma (LELC) Response to PD-L1 Blockade. Clin. Lung Cancer, 2018, 20, 20. PMID: 30679078
  19. Qiu, Z.X.; Zhou, P.; Wang, K. Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab: A case report. OncoTargets Ther., 2019, 12, 8595-8600. doi: 10.2147/OTT.S219512 PMID: 31802895
  20. Xiao, Y.; He, J.; Luo, S. Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: A retrospective study. Front. Oncol., 2022, 12, 820302. doi: 10.3389/fonc.2022.820302
  21. Tang, Z.; Fang, R.; Tong, G. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature. Lung Cancer, 2020, 146, 335-340. doi: 10.1016/j.lungcan.2020.06.027
  22. Dolesche, D. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J. Exp. Clin. Cancer Res., 2021, 40, 288.
  23. Manegold, C. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J. Thorac. Oncol., 2017, 12, 194-207.
  24. Han, B.; Li, K.; Wang, Q.; Zhang, L.; Shi, J.; Wang, Z.; Cheng, Y.; He, J.; Shi, Y.; Zhao, Y.; Yu, H.; Zhao, Y.; Chen, W.; Luo, Y.; Wu, L.; Wang, X.; Pirker, R.; Nan, K.; Jin, F.; Dong, J.; Li, B.; Sun, Y. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer. JAMA Oncol., 2018, 4(11), 1569-1575. doi: 10.1001/jamaoncol.2018.3039 PMID: 30098152
  25. Chu, T.; Zhong, R. Zhong, H Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J. Thorac. Oncol., 2021, 16(4), 643-652. doi: 10.1016/j.jtho.2020.11.026
  26. Wang, P.; Fang, X.; Yin, T. Efficacy and safety of Anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front. Oncol., 2021, 11, 628124. doi: 10.3389/fonc.2021.628124
  27. Liu, S.; Qin, T.; Liu, Z. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis., 2020, 11(5), 309. doi: 10.1038/s41419-020-2511-3
  28. Liu, Y.; Long, L.; Liu, J. Case report: Anlotinib reverses nivolumab resistance in advanced primary pulmonary lymphoepithelioma-like carcinoma with FGFR3 gene amplification. Front. Oncol., 2021, 11, 749682. doi: 10.3389/fonc.2021.749682
  29. Ramjiawan, R.R.; Griffioen, A.W.; Duda, D.G. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis, 2017, 20(2), 185-204. doi: 10.1007/s10456-017-9552-y
  30. Lee, W.S.; Yang, H.; Chon, H.J. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med., 2020, 52(9), 1475-1485. doi: 10.1038/s12276-020-00500-y
  31. Ren, S.; He, J.; Fang, Y. Camrelizumab plus Apatinib in treatment-naive patients with advanced nonsquamous NSCLC: A multicenter, open-label, single-arm, phase 2 trial. JTO Clin. Res. Rep., 2022, 3(5), 100312. doi: 10.1016/j.jtocrr.2022.100312
  32. Kudo, M.; Finn, R.S.; Cheng, A.L. Albumin-Bilirubin grade analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc analysis of the Phase III IMbrave150 study. Liver Cancer, 2023, 12(5), 479-493. doi: 10.1159/000529996

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024